Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab and Bendamustine in Relapsed or Refractory CLL
NCT01466153Phase 2Completed
- Sponsor
- MedImmune
- Start
- Feb 2012
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of inebilizumab in chronic lymphocytic leukemia (CLL), sponsored by MedImmune. Started Feb 2012; status: completed.
02
Drugs
inebilizumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01466153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01466153.